I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib

Lung Cancer

Volumn 88, Issue 2, 2015, Pages 231-234

  Ou, Sai Hong Ignatius ^a,b   Greenbowe, Joel ^c   Khan, Ziad U ^a,b   Azada, Michele C ^a,b   Ross, Jeffrey S ^c,d   Stevens, Phil J ^c   Ali, Siraj M ^c   Miller, Vincent A ^c   Gitlitz, Barbara ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c FOUNDATION MEDICINE   (United States)

^d ALBANY MEDICAL CENTER   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alectinib; ALK rearranged non small cell lung cancer; Ceritinib; Crizotinib; I1171 missense mutation; I1171N; I1171S; I1171T

Indexed keywords

ALANINE AMINOTRANSFERASE; ALECTINIB; ALKALINE PHOSPHATASE; ANAPLASTIC LYMPHOMA KINASE; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; CERITINIB; CRIZOTINIB; CARBAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; SULFONE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; JAUNDICE; LIVER BIOPSY; LIVER METASTASIS; MIDDLE AGED; MISSENSE MUTATION; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; PATHOLOGY;

CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION, MISSENSE; PIPERIDINES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SULFONES;

EID: 84926421697     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.02.005     Document Type: Article

References (12)

1. Ou S.H., Azada M., Hsiang D.J., Herman J.M., Kain T.S., Siwak-Tapp C., et al. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 2014, 9:549-553.
2. Katayama R., Friboulet L., Koike S., Lockerman E.L., Khan T.M., Gainor J.F., et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK Inhibitor alectinib. Clin Cancer Res 2014, 20:5686-5696.
3. Ou S.H., Klempner S.J., Greenbowe J.R., Azada M., Schrock A.B., Ali S.M., et al. Identification of a novel HIP1-ALK fusion variant in non-small-cell lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to alectinib. J Thorac Oncol 2014, 9:1821-1825.
4. Toyokawa G., Hirai F., Inamasu E., Yoshida T., Nosaki K., Takenaka T., et al. Secondary mutations at I1171 in the ALK gene confer resistance to both crizotinib and alectinib. J Thorac Oncol 2014, 9:e86-e87.
5. Zhang S., Wang F., Keats J., Zhu X., Ning Y., Wardwell S.D., et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des 2011, 78:999-1005.
6. Ceccon M., Mologni L., Bisson W., Scapozza L., Gambacorti-Passerini C. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res 2013, 11:122-132.
7. Zdzalik D., Dymek B., Grygielewicz P., Gunerka P., Bujak A., Lamparska-Przybysz M., et al. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. J Cancer Res Clin Oncol 2014, 140:589-598.
8. Gettinger S.N., Bazhenova L., Salgia R., Langer C.J., Gold K.A., Rosell R., et al. Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol 2014, 32(5s). [suppl; abstr 8047].
9. Bossi R.T., Saccardo M.B., Ardini E., Menichincheri M., Rusconi L., Magnaghi P., et al. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry 2010, 49:6813-6825.
10. Kornev A.P., Haste N.M., Taylor S.S., Eyck L.F. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci USA 2006, 103:17783-17788.
11. Friboulet L., Li N., Katayama R., Lee C.C., Gainor J.F., Crystal A.S., et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014, 4:662-673.
12. [assessed 12.01.15]. http://www.xalkori.com/sites/default/files/documents/Xalkori_PI.pdf.